Formulation of Furosemide Oral Disintegrating Tablets Using Natural and Synthetic Superdisintegrants by SeDeM Expert Design System
SeDeM design expert technique used to evaluate the risks of poor flow of pharmaceutical powders under preformulation studies which reveals direct compression suitability and prepare robust composition of active pharmaceutical ingredient (API) and excipient in tablets formulation. The purpose of this study was to develop oral disintegrating tablets of Furosemide using different concentration of natural and synthetic superdisintegrants by means of SeDeM design technique. Oral disintegrating tablets (ODT) of Furosemide were prepared by direct compression technique using isolated banana powder and croscarmellose sodium (Ac-di-sol) together with microcrystalline cellulose as superdisintegrants. SeDeM design was performed to check suitability and deficient of excipients and drug for optimized composition derived based on IPP value. These tablets were evaluated for hardness, friability, drug content, weight variation, wetting time and in-vitro dissolution. All the formulations showed low weight variation with dispersion time less than 173.5±0.70 seconds and rapid in-vitro dissolution. The drug content of all the formulations was within the acceptable limits. Lubricated blend composition of F4 found average radius value 5.24, 0.66 and 5.509 for IGC, IP and IPP respectively, compressed tablet shown good physical properties. The optimized formulation F4 showed good release profile with 99.25 percentage drug release compared to other trial batches. It was concluded that natural superdisintegrant (banana powder) showed better disintegrating property than synthetic super disintegrant (Ac-di-sol) in the formulations of ODTs.
Keywords: Furosemide, Oral disintegrating tablets, SeDeM expert system, Superdisintegrants
2. Negre JM, Montoya EG, Lozano PP, Diaz JEA, Carreras MR, Garcia RF, Grau JRT, SeDeM diagram: a new expert system for the formulation of drugs in solid form, In Expert systems for human, materials and automation, 2011 Oct 10, IntechOpen.
3. Aguilar-Diaz JE, Garcia-Montoya E, Perez-Lozano P, Sune-Negre JM, Minarro M, Tico JR, SeDeM expert system a new innovator tool to develop pharmaceutical forms, Drug Development and Industrial Pharmacy, 2014; 40(2): 222-236.
4. Chaulang G, Patel P, Hardikar S, Kelkar M, Bhosale A, Bhise S, Formulation and Evaluation of Solid Dispersions of Furosemide in Sodium Starch Glycolate, 2009; 8(February): 43–51.
5. Gulbag S, Yılmaz Usta D, Gultekin HE, Oktay AN, Demirtas O, Karakucuk A, Çelebi N, New perspective to develop memantine orally disintegrating tablet formulations: SeDeM expert system, Pharmaceutical Development and Technology, 2018; 23(5): 512-519.
6. Bhavsar PH, Bhatt B, Oza C, Trivedi S, Shah S. A review on: SeDeM expert system in formulation development of pharmaceutical forms, J Pharm Sci Bioscientific Res, 2015; 5(4): 363-9.
7. Singh I, Kumar P, Preformulation studies for direct compression suitability of cefuroxime axetil and paracetamol: a graphical representation using SeDeM diagram, Acta Pol Pharm, 2012; 69(1): 87e93.
8. Tadwee I, Shahi S, Formulation development of losartan potassium immediate release tablets and process optimization using SeDeM expert system, J Appl Pharm Sci,2018; 8(2): 33-43.
9. Indian Pharmacopeia, Ministry of Health and Family welfare, 1996; volume II, 3.12.
10. Aguilar_Diaz JE, Garcia-Montoya E, Perez-Lozano P, Sune-Negre JM, Minarro M, TicoJR, The use of the SeDeM Diagram expert system to determine the suitability of diluents-disintegrants for direct compression and their use in formulation of ODT, Eur J Pharm & Biopharm, 2009; 73: 414-423.
11. Tadwee I, Shahi Sadhana, Zaheer Zahed, Preformulation studies using lactose in development of solid oral dosage form: a graphical representation using SeDeM method, Int J Curr Pharm Res 2017; 9(5):168-172.
12. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, IIDA K, Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity, Chem Pharm Bull,1996; 44: 2121-2127.
13. ICH stability guidelines “Stability Testing of New Drug Substances and Products” Q1A (R2) 6 February 2003.
14. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S, Sublingual administration of furosemide: new application of an old drug, Br J Clin Pharmacol, 2007; 64: 804-809.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).